News
Commission launches call for proposals to develop AI Excellence Centres
On 12 July, the European Commission has launched a call for proposals to develop a European network of artificial intelligence (AI) centres. Proposals for the call may be submitted up till 13 November 2019.
Developments on German EU Council Presidency
The presidency of the Council of the European Union (EU Council), the EU institution gathering the government ministers from each EU country, rotates among the EU member states every 6 months. During this 6-month period, the presidency chairs meetings at every level in the Council, helping to ensure the continuity of the EU's work in the Council. More importantly, the presidency is responsible for driving forward the Council's work on EU legislation, ensuring the continuity of the EU agenda, orderly legislative processes and cooperation among member states.
Commission launches online consultation to shape Horizon Europe
On 16 July, the European Commission published an orientation paper and launched an online consultation on the strategic priorities of Horizon Europe, the EU’s next framework programme for research and innovation (R&I). The consultation opens until 8 September and is addressed to individuals and organisations with an interest in the future EU R&I priorities.
Avicenna Alliance continues to grow and is proud to announce the newest addition to its list of members
The Avicenna Alliance is happy to welcome its newest member: ELEM Biotech
EU invests €35 million to develop AI solutions for cancer prevention, diagnostics and treatment
On 9 July, the European Commission has launched a call for proposal with €35 million available aimed to support the development of analysis of health images for cancer diagnostics based on Artificial Intelligence (AI).
Dassault to enhance clinical tech with Medidata acquisition
Dassault Systèmes acquired Medidata, major player in information technologies for clinical trials, for $5.5 billion. This represents to date the largest buyout in the emerging area of in silico medicine and in silico trials and "a significant milestone to address the complexity of developing personalied medicine and patient-centric experiences".
